	US 12,435,353 B2
	Biomarker assay for use in monitoring autism
Lynn Durham, Geneva (CH)
Assigned to STALICLA SA, Geneva (CH)
Filed by STALICLA SA, Geneva (CH)
Filed on Sep. 20, 2023, as Appl. No. 18/470,985.
Application 18/470,985 is a continuation of application No. 16/761,926, abandoned, previously published as PCT/EP2018/080375, filed on Nov. 6, 2018.
Claims priority of provisional application 62/582,213, filed on Nov. 6, 2017.
Claims priority of application No. 17200220 (EP), filed on Nov. 6, 2017.
Prior Publication US 2024/0011071 A1, Jan. 11, 2024
Int. Cl. C12Q 1/48 (2006.01)

CPC C12Q 1/485 (2013.01)

2 Claims

1. A method of treatment comprising:

providing a sample of bodily fluid from a patient,

measuring protein kinase A levels in the sample,

identifying the patient as being an autism spectrum disorder (ASD) phenotype 1 if the protein kinase A levels measured in the sample are lower than protein kinase A levels in an age- and sex-matched control sample, and

treating the patient by administering a therapeutically effective amount of ibudilast and bumetanide.